Reviewing the journey to the clinical application of bacteriophages to treat multi-drug-resistant bacteria

Gerald Mboowa

doi:10.1186/s12879-023-08621-1

Reviewing the journey to the clinical application of bacteriophages to treat multi-drug-resistant bacteria

BMC Infect Dis. 2023 Oct 3;23(1):654. doi: 10.1186/s12879-023-08621-1.

Author

Gerald Mboowa^{1

2}

Affiliations

¹ African Centre of Excellence in Bioinformatics and Data-Intensive Sciences, the Infectious Diseases Institute, College of Health Sciences, Makerere University, P.O Box 22418, Kampala, Uganda. gmboowa@gmail.com.
² Africa Centres for Disease Control and Prevention, African Union Commission, Roosevelt Street, P.O. Box 3243, Addis Ababa, W21 K19, Ethiopia. gmboowa@gmail.com.

Abstract

Antimicrobial resistance (AMR) was a leading cause of death globally in 2019. Sadly, COVID-19 has exacerbated AMR, nonetheless, the process of developing new antibiotics remains very challenging. This urgently requires the adoption of alternative approaches to treat multi-drug-resistant bacterial infections. This editorial introduces the 'Bacteriophages against multi-drug resistant bacteria' collection launched at BMC Infectious Diseases which highlights progress towards using bacteriophages to tackle AMR.

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Bacteria
Bacterial Infections* / drug therapy
Bacteriophages*
COVID-19*
Drug Resistance, Bacterial
Drug Resistance, Multiple, Bacterial
Humans

Substances

Anti-Bacterial Agents